TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Brain Metastases|HER2-positive Breast Cancer|CNS Disease
Interventions: DRUG: Tucatinib|DRUG: Pembrolizumab|DRUG: Trastuzumab
Sponsor: Reva Basho
Collaborators: Merck Sharp & Dohme LLC|Seagen Inc.